Secretome Therapeutics, a pioneering company in the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01, the ...

Pint Pharma and PharmaEssentia announced today that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment of adult patients with Polycythemia ...

Type B Meeting Discussion to Accelerate XRx-026 for Gout to NDA CALGARY, Alberta, March 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Fra ...

Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and ...

Vera Therapeutics, Inc. (NASDAQ: VERA) has reported its financial results for the fourth quarter and full year ended December 31, 2024. The company's net loss for the year ended December 31, 2024, was ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) is expected to be releasing its earnings data before the market opens on Wednesday, March 19th. Analysts expect Vera Therapeutics to post earnings of ...

Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.